Selexis Will Apply the SURE CHO-Mplus Libraries™ to Achieve OptimalExpression Results with a Difficult-to-Express Protein
Geneva, Switzerland, September 22, 2015 – Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with rare diseases.
Under the agreement, Selexis will use the SURE CHO-Mplus Libraries to address issues with difficult-to-express proteins.
“With the application of our new technologies, we are pleased to help Sobi reach their protein expression goal,” said Marco Bocci, PhD, vice president of business development and licensing of Selexis. “Our recent efforts in deciphering our CHO-M cell line is making a footprint in helping biopharmaceutical companies with advancing difficult-to-express proteins into the clinic and ultimately the patient.”
Web www.selexis.com
LinkedIn www.linkedin.com/company/selexis-sa
Twitter www.twitter.com/SelexisSA
Facebook www.facebook.com/SelexisSA
Contact details
-
- Sarah Wakefield
-
KBI Biopharma Company Inquiries
SVP, Corporate Communications - swakefield@kbibiopharma.com
Related topics
Related news
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chi...
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...
KBI Biopharma Continues to Strengthen Leadership and Expertise With Key Executive Appointments
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.